After failing to significantly extend survival in a confirmatory Phase 3 trial, Keytruda (pembrolizumab) will no longer be available in the U.S. for people with previously treated metastatic small ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Immunocore ‘s tebentafusp (IMCgp100) for HLA-A2 positive, inoperable, or advanced uveal melanoma — a common ...

The European Commission has approved Opdivo (nivolumab) as a second-line treatment for adults with advanced inoperable, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC), who ...

DNX-2401 is an oncolytic immunotherapy being investigated by DNAtrix for the treatment of cancers, especially brain tumors. Oncolytic viruses, infect and destroy cancer cells while leaving normal ...

JNJ-61186372 is a bispecific antibody being jointly developed by Genmab and Janssen for the treatment of cancer. The treatment is currently in Phase 1 clinical trial for the treatment of patients with ...

rSIFN-co is a potential cancer therapy that Sichuan Huiyang Life Science and Technology Corporation is developing to treat several types of advanced solid tumors. How rSIFN-co works rSIFN-co, or ...

The U.S. Food and Drug Administration (FDA) has approved the immunotherapy Tecentriq (atezolizumab), in combination with Cotellic (cobimetinib) and Zelboraf (vemurafenib), for the treatment of BRAF ...

Researchers at Uppsala University, in Sweden, in collaboration with the SciLifeLab Drug Discovery and Development Platform, have taken “a large step forward” in developing a potential CAR T-cell ...

The Chinese National Medical Products Administration (NMPA) has approved Keytruda (pembrolizumab) as a second-line therapy for patients with locally advanced or metastatic esophageal squamous cell ...

TVI-Brain-1, an immunotherapy being developed by TVAX Biomedical, was given fast track designation by the U.S. Food and Drug Administration (FDA) as a potential treatment of glioblastoma multiforme, a ...

A combination of ONCOS-102 plus standard chemotherapy continues to extend the time without disease progression and appears to induce immune system activity in people with malignant pleural ...

A subset of women with recurrent or advanced endometrial cancer, whose disease progressed on or after platinum-based chemotherapy, achieved clinically meaningful responses after treatment with ...